JPS57156421A - Malaria vaccine and its preparation - Google Patents

Malaria vaccine and its preparation

Info

Publication number
JPS57156421A
JPS57156421A JP56042778A JP4277881A JPS57156421A JP S57156421 A JPS57156421 A JP S57156421A JP 56042778 A JP56042778 A JP 56042778A JP 4277881 A JP4277881 A JP 4277881A JP S57156421 A JPS57156421 A JP S57156421A
Authority
JP
Japan
Prior art keywords
malaria
erythrocyte
attenuated
protozoan
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56042778A
Other languages
Japanese (ja)
Other versions
JPH0224806B2 (en
Inventor
Seiji Waki
Mamoru Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIHON KOUTAI KENKYUSHO KK
NIPPON KOUTAI KENKYUSHO KK
Original Assignee
NIHON KOUTAI KENKYUSHO KK
NIPPON KOUTAI KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIHON KOUTAI KENKYUSHO KK, NIPPON KOUTAI KENKYUSHO KK filed Critical NIHON KOUTAI KENKYUSHO KK
Priority to JP56042778A priority Critical patent/JPS57156421A/en
Publication of JPS57156421A publication Critical patent/JPS57156421A/en
Publication of JPH0224806B2 publication Critical patent/JPH0224806B2/ja
Granted legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

PURPOSE: To obtain a malaria vaccine, by attenuating a malaria protozoan, inoculating it to a vertebrate animal of thymus imcompetence, collecting the erythrocyte containing the attenuated malaria protozoan.
CONSTITUTION: A mouse, aotus, etc. is infected by a malaria protozoan (e.g., plasmodium berghei, plasmodium falciparum, etc.), the erythrocyte is irradiated with X-rays and the malaria protozoan is attenuated. It is then inculated into a vertebrate animal (e.g., mouse, aotus, etc.) of thymus incompetence. Preferably 15W40 days after the inoculation, its erythrocyte is separated and collected. The prepared erythrocyte containing the attenuated malaria notozoan is directly preserved at preferably -100W-50°C, and used as a vaccine. A dose is 104W 107 (erythrocyte)/kg weight one W twice in intravenous, intraperitoneal, intramuscular, and hypodermic medication.
COPYRIGHT: (C)1982,JPO&Japio
JP56042778A 1981-03-24 1981-03-24 Malaria vaccine and its preparation Granted JPS57156421A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56042778A JPS57156421A (en) 1981-03-24 1981-03-24 Malaria vaccine and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56042778A JPS57156421A (en) 1981-03-24 1981-03-24 Malaria vaccine and its preparation

Publications (2)

Publication Number Publication Date
JPS57156421A true JPS57156421A (en) 1982-09-27
JPH0224806B2 JPH0224806B2 (en) 1990-05-30

Family

ID=12645418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56042778A Granted JPS57156421A (en) 1981-03-24 1981-03-24 Malaria vaccine and its preparation

Country Status (1)

Country Link
JP (1) JPS57156421A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002917A1 (en) * 1983-01-28 1984-08-02 Inst Medical W & E Hall EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA
US8802919B2 (en) * 2002-04-05 2014-08-12 Sanaria Inc. Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production
US8821896B2 (en) 2009-01-16 2014-09-02 Sanaria Inc. Purified Plasmodium and vaccine composition
US9278125B2 (en) 2011-05-11 2016-03-08 Sanaria Inc. Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants
US9764016B2 (en) 2013-01-25 2017-09-19 Sanaria Inc. Genetic attenuation of Plasmodium by B9 gene disruption

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002917A1 (en) * 1983-01-28 1984-08-02 Inst Medical W & E Hall EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA
US8802919B2 (en) * 2002-04-05 2014-08-12 Sanaria Inc. Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production
US8821896B2 (en) 2009-01-16 2014-09-02 Sanaria Inc. Purified Plasmodium and vaccine composition
US8992944B2 (en) 2009-01-16 2015-03-31 Sanaria Inc. Purified Plasmodium and vaccine composition
US9241982B2 (en) 2009-01-16 2016-01-26 Sanaria Inc. Purified plasmodium and vaccine compositions
US9616115B2 (en) 2009-01-16 2017-04-11 Sanaria Inc. Purified plasmodium and vaccine compositions
US10272146B2 (en) 2009-01-16 2019-04-30 Sanaria Inc. Purified plasmodium and vaccine compositions
US9278125B2 (en) 2011-05-11 2016-03-08 Sanaria Inc. Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants
US9642909B2 (en) 2011-05-11 2017-05-09 Sanaria Inc. Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants
US9764016B2 (en) 2013-01-25 2017-09-19 Sanaria Inc. Genetic attenuation of Plasmodium by B9 gene disruption
US9931389B2 (en) 2013-01-25 2018-04-03 Sanaria Inc. Genetic attenuation of plasmodium by B9 gene disruption

Also Published As

Publication number Publication date
JPH0224806B2 (en) 1990-05-30

Similar Documents

Publication Publication Date Title
Nussenzweig et al. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites
Kilejian et al. Plasmodium falciparum and Plasmodium coatneyi: immunogenicity of “knob-like protrusions” on infected erythrocyte membranes
Beaudoin et al. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen
ATE165978T1 (en) ATTENUATED, GENETICALLY ENGINEERED PSEUDORABIES VIRUS S-PRV-155 AND ITS USES
ES2176232T3 (en) ADEQUATE VACCINE TO BE USED IN THE PREVENTION AND TREATMENT OF INFECTION WITH HELICOBACTER.
Kamil et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers
Liew et al. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
FI842215A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV LEVANDE EFFEKTIVERINGSVACCIN OCH PAO DETTA SAETT ERHAOLLNA VACCIN.
JPS5649323A (en) Coccidiostat
JPS57156421A (en) Malaria vaccine and its preparation
Ek et al. Mercury exposure and murine response to Plasmodium yoelii infection and immunization
Playfair et al. Vaccination of mice against malaria with soluble antigens. I. The effect of detergent, route of injection, and adjuvant
Renia et al. Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage.
CN104771752B (en) Malaria erythrocytic stage inactivates the new application of full worm vaccine
Gordon Smith et al. Mechanisms of malarial immunity
Baughn et al. Altered immune responsiveness associated with experimental syphilis in the rabbit: elevated IgM and depressed IgG responses to sheep erythrocytes
Davis et al. Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP) 3
JPS57112331A (en) Medical composition of ganoderma lucidum component
Golenser et al. Dynamics of thymidine incorporation by spleen cells from rats infected with Plasmodium berghei.
JPS57192318A (en) Preventing method of filarial disease
De Buck Infection experiments with quartan malaria
JPS57159720A (en) Prevention of leucocytozoonosis
Wells et al. Plasmodium yoelii: an inbred model for protective immunization against malaria in BALB/c mice
Le Bras et al. Malaria, arbovirus and hepatitis infections in Macaca fascicularis from Malaysia
Davenport Present status of inactivated influenza virus vaccines